Mosunetuzumab-axgb: A New Hope for Relapsed or Refractory Follicular Lymphoma Patients
Introduction: Follicular lymphoma (FL) is a type of non-Hodgkin’s lymphoma that arises from abnormal lymphocytes. While several treatment options are available, relapse or refractory disease remains a significant challenge. Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engager developed by Genentech, Inc. It is approved for adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
Efficacy: The patients with relapsed or refractory FL were treated with mosunetuzumab-axgb. The overall response rate (ORR) was 80%, with 60% achieving complete responses. Among responders, the estimated median duration of response (DOR) was 22.8 months, and the estimated DOR rate at 12 months and 18 months was 62% and 57%, respectively. These results suggest that mosunetuzumab-axgb can provide durable responses in patients with relapsed or refractory FL.
Safety: Mosunetuzumab-axgb can cause serious or life-threatening cytokine release syndrome (CRS), a potentially dangerous side effect that can occur when T cells are activated by the drug. Other warnings and precautions include neurologic toxicity, infections, cytopenias, and tumor flare. Therefore, close monitoring and supportive care are essential for patients receiving mosunetuzumab-axgb.
Mosunetuzumab-axgb is a promising treatment option for adult patients with relapsed or refractory FL after two or more lines of systemic therapy. It has shown impressive efficacy with a high ORR and durable responses. However, it also comes with potentially severe side effects, which require careful monitoring and management. With continued research and development, mosunetuzumab-axgb has the potential to improve the outcomes of patients with FL and other CD20-positive malignancies. The use of mosunetuzumab-axgb for the treatment of relapsed or refractory follicular lymphoma should be discussed with a physician or other qualified healthcare provider, who can evaluate the individual patient’s medical history and provide appropriate recommendations.
